Hamaguchi M, Kojima T. Favorable effect of modest alcohol consumption to fatty liver disease. World J Gastroenterol 2013; 19(32): 5393-5394 [PMID: 23983447 DOI: 10.3748/wjg.v19.i32.5393]
Corresponding Author of This Article
Masahide Hamaguchi, MD, PhD, Department of Experimental Immunology, World Premier International Immunology Frontier Research Center, Osaka University, Yamadaoka, 1-1, Suita 565-0871, Japan. mhamaguchi@ifrec.osaka-u.ac.jp
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letters To The Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Masahide Hamaguchi, Department of Experimental Immunology, World Premier International Immunology Frontier Research Center, Osaka University, Suita 565-0871, Japan
Takao Kojima, Department of Gastroenterology, Murakami Memorial Hospital, Asahi University, Gifu 500-8523, Japan
ORCID number: $[AuthorORCIDs]
Author contributions: Hamaguchi M and Kojima T wrote this letter; Hamaguchi M revised the letter.
Supported by Young Scientists (B) from Japan Society for the Promotion of Science, No. 23790791
Correspondence to: Masahide Hamaguchi, MD, PhD, Department of Experimental Immunology, World Premier International Immunology Frontier Research Center, Osaka University, Yamadaoka, 1-1, Suita 565-0871, Japan. mhamaguchi@ifrec.osaka-u.ac.jp
Telephone: +81-6-68794963 Fax: +81-6-68794464
Received: May 3, 2013 Revised: July 9, 2013 Accepted: July 17, 2013 Published online: August 28, 2013 Processing time: 115 Days and 23.6 Hours
Abstract
We previously reported that modest alcohol consumption was significantly inversely associated with fatty liver disease. Feng et al pointed out a discrepancy of statistical significance between our current larger scale cohort and a previous cohort. However, the prevalence of non-alcoholic fatty liver disease was higher in non or minimal drinkers than those in light drinkers in both cohorts. They also argue that some potential co-factors such as soft drink consumption and genetic variations should be discussed.
Core tip: We reported the inversed association of modest alcohol consumption with fatty liver disease. However, other potential co-factors were argued to be important. Herein, we reply and discuss these important factors in this letter.
Citation: Hamaguchi M, Kojima T. Favorable effect of modest alcohol consumption to fatty liver disease. World J Gastroenterol 2013; 19(32): 5393-5394
Feng et al argued against the validity of the category of alcohol consumption we used, however this categorization was made in accordance with standardized methods[1,2]. They also pointed out the discrepancy of statistical significance between our current larger scale cohort and a previous cohort[3-5]. However, the prevalence of non-alcoholic fatty liver disease (NAFLD) was higher in non or minimal drinker than those in light drinker in both cohorts. In the current cohort, the prevalence of NAFLD was higher in non or minimal drinkers than those in light drinkers both in men (36.5%, 2248/6154 vs 26.4%, 457/1734) and in women (10.4%, 719/6893 vs 5.4%, 22/406)[4]. A similar trend was reported in the previous cohort as follows; the prevalence of NAFLD was higher in non or minimal drinkers than those in light drinkers both in men (28.6%, 170/595 vs 23.5%, 464/1977) and in women (10.7%, 105/981 vs 8.6%, 73/848)[5]. While statistical significance was not detected in the cohort used in our previous study, however we speculated that the smaller size of the cohort may have reduced the power of the statistical test and thus failed to detect the difference. Moreover, we previously reported that there is a favorable effect of modest alcohol consumption for the development of NAFLD in a prospective cohort study[6]. The adjusted odds ratio of light drinkers for the development of NAFLD was 0.82 (0.59-1.15, P = 0.26) in men, and 0.86 (0.51-1.45, P = 0.56) in women, respectively. The odds ratio was not statistically significant, but the possibility of a favorable effect was speculated[6].
Feng et al[3] also argue that soft drink consumption or genetic variations may be potential co-factors for the favorable effect of modest alcohol consumption to fatty liver disease. Soft drink consumption is an important risk factor for NAFLD[7]. Unfortunately, in this case we had no data of soft drink consumption. However, a previous study has reported no association between alcohol consumption and soft drink consumption[8]. Thus, the association of NAFLD with soft drink consumption may be independent of those with alcohol consumption.
Genetic variations have been reported as important risk factors for NAFLD and non-alcoholic steatohepatitis[9-13]. The mechanisms of these genetic variations for development of NAFLD are still largely unknown. Thus, future investigations are needed; however, we appreciated Dr. Feng’s extension of our discussion regarding the role of genetic variations in the pathophysiology of NAFLD.
In conclusion, we reported the inverted association of modest alcoholic consumption with fatty liver disease in a large scale cross-sectional study. Future large scale prospective studies and basic investigations are needed to clarify the effect of modest alcohol consumption in the development of fatty liver disease.
Footnotes
P- Reviewers Dalamaga M, Pan Q, Tiribelli C, Wu JA S- Editor Wen LL L- Editor A E- Editor Zhang DN
Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.Ann Intern Med. 2005;143:722-728.
[PubMed] [DOI][Cited in This Article: ]
Raszeja-Wyszomirska J, Kurzawski G, Lawniczak M, Miezynska-Kurtycz J, Lubinski J. Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study.World J Gastroenterol. 2010;16:2531-2536.
[PubMed] [DOI][Cited in This Article: ]
Rey JW, Noetel A, Hardt A, Canbay A, Alakus H, Zur Hausen A, Dienes HP, Drebber U, Odenthal M. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases.World J Gastroenterol. 2010;16:5830-5837.
[PubMed] [DOI][Cited in This Article: ]
Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JB, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day CP. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies.J Hepatol. 2012;56:448-454.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 124][Cited by in F6Publishing: 124][Article Influence: 10.3][Reference Citation Analysis (0)]